Preeti Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Preeti Yadav has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Diksha Mishra
Research Scholar, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India
1 shared publication- Niti Sharma
Department of Pharmacology, Lloyd Institute of Management and Technology, Greater Noida, India
1 shared publication Rahul Kaushik
Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India
1 shared publication- Rajan Kumar Kurmi
Department of Chemistry, Metro College of Health Sciences and Research, Greater Noida, India
1 shared publication Rajan Kurmi
Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India
1 shared publicationSanket Sharma
Research Scholar, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by Springer Nature in Nutrire
- Vol. 51 (1) , 10
Exploring micronutrient diets in renal disease through metabolomics: a comprehensive review
- 30 January 2026
- Published by Springer Nature in Nutrire
- Vol. 51 (1) , 10
Open AccessExploring micronutrient diets in renal disease through metabolomics: a comprehensive review
- Open Access
- 18 May 2025
- Published by Journal of Applied Pharmaceutical Sciences and Research in Journal of Applied Pharmaceutical Sciences and Research
- Vol. 8 (01) , 43-51
IN-SILICO EVALUATION OF TETRAMETHYL-PYRAZINE: TREATING RECURRING SEIZURES
Epilepsy, a chronic neurological disorder characterized by recurrent seizures, remains a challenging condition to treat due to the limited availability of potent and safe molecules. This study explores Tetramethyl-pyrazine (TMP) as a potential scaffold for epilepsy treatment, leveraging its diverse pharmacological properties. Utilizing structure-based virtual screening, we identified 300 active ligands from a virtual chemical library of 4427 compounds, narrowing down to the top 7 potential ligands for GABA-AT inhibitor properties based on binding energy, drug-likeness, non-covalent interactions, and toxicity. Our results revealed a compound (PubChem ID 227746) with high binding affinity to protein 4MS4, strong interactions within the active site, and favorable pharmacokinetic and toxicological properties, suggesting TMPz holds promise as an anti-epileptic agent.
- 18 May 2025
- Published by Journal of Applied Pharmaceutical Sciences and Research in Journal of Applied Pharmaceutical Sciences and Research
- Vol. 8 (01) , 43-51
Open AccessIN-SILICO EVALUATION OF TETRAMETHYL-PYRAZINE: TREATING RECURRING SEIZURES
Epilepsy, a chronic neurological disorder characterized by recurrent seizures, remains a challenging condition to treat due to the limited availability of potent and safe molecules. This study explores Tetramethyl-pyrazine (TMP) as a potential scaffold for epilepsy treatment, leveraging its diverse pharmacological properties. Utilizing structure-based virtual screening, we identified 300 active ligands from a virtual chemical library of 4427 compounds, narrowing down to the top 7 potential ligands for GABA-AT inhibitor properties based on binding energy, drug-likeness, non-covalent interactions, and toxicity. Our results revealed a compound (PubChem ID 227746) with high binding affinity to protein 4MS4, strong interactions within the active site, and favorable pharmacokinetic and toxicological properties, suggesting TMPz holds promise as an anti-epileptic agent.